ArticleFrontiers in cardiovascular medicine2025
Correlation between serum cyclophilin A and acute ST-segment elevation myocardial infarction and its predictive value.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute ST-segment elevation myocardial infarction (STEMI) is a serious cardiovascular event, and timely diagnosis and intervention are essential to improve prognosis. As a novel biomarker, serum cyclophilin A (CyPA) may play an important role in the development and progression of STEMI. Methods: Two hundred and sixty-four patients with acute STEMI and 264 healthy controls were included in this study. The association of CyPA with STEMI was assessed by multivariate logistic regression analysis, and the potential value of CyPA in predicting STEMI risk was assessed using receiver operating characteristic curve (ROC) and reclassification analysis. In addition, calibration curves and decision curve analysis (DCA) were used to test the reliability of CyPA in predicting STEMI risk. Results: The results showed that serum CyPA levels were significantly higher in patients with acute STEMI than in healthy controls ( Conclusion: This study showed that serum cyclophilin A levels were closely associated with the development of acute ST-segment elevation myocardial infarction. CyPA may become a potential biomarker for acute STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.